Endocrinologists should take lead on thyroid eye disease care
The availability of new treatments for thyroid eye disease provides endocrinologists an opportunity to take the lead in managing the disease, according to an article published in AACE Endocrinology and Diabetes.
In decades past, thyroid eye disease was a challenging condition to treat due to the lack of therapy options outside of steroids, said Thanh D. Hoang, DO, MACP, FACE, professor of medicine at the Uniformed Services University of the Health Sciences. However, the FDA approval of teprotumumab-trbw (Tepezza, Amgen) in 2020 and veligrotug-vvze (Lumvoa, Viridian Therapeutics) in 2026 have